The challenge of managing relapsed or refractory B-cell malignancies continues to thwart the efforts of oncologists and ...

The FDA has approved a new subcutaneous (SC) formulation of pembrolizumab (Keytruda Qlex), co-formulated with ...

Helena Yu, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the treatment landscape of EGFR exon 20 insertion (ex20ins)-mutated non–small cell lung cancer (NSCLC) and how ...

In small cell lung cancer (SCLC), the protein DLL3 is a promising target in the development of emerging therapies. In particular, DLL3-targeted therapies have been integral in ant ...

Survival and Progression Metrics: Secondary and exploratory endpoints include duration of response, sustained MRD negativity, biochemical and clinical progression-free survival (PFS), time to a ...

Mitazalimab, in combination with standard chemotherapy, has exhibited continued promising efficacy and safety in treating ...

Michael Cole shares his decade-long battle with malignant pleural mesothelioma, highlighting treatment choices, resilience, and the vital doctor-patient relationship.

Michael Cole shares his decade-long battle with malignant pleural mesothelioma, highlighting treatment choices, resilience, and the vital doctor-patient relationship.

Combination therapy with relatlimab and nivolumab enhances treatment-free survival in advanced melanoma, offering promising ...

The study evaluated lifileucel in patients 18 years and older with unresectable or metastatic melanoma (stage IIIc or IV) who ...

The JAVELIN Bladder 100 trial established avelumab (Bavencio) as a standard switch maintenance therapy, according to Grivas.

FDA lifts REMS program for vandetanib, affirming safety in thyroid cancer treatment as healthcare providers ensure effective ...